4-year watch on Jivi's safety for hemophilia a patients
NCT ID NCT04461639
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This study follows 62 people with hemophilia A who are already using Jivi (a long-acting clotting factor) to prevent bleeding. Researchers will track safety events like side effects and lab changes over at least 4 years during routine doctor visits. The goal is to better understand the long-term safety of this medication in real-world use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Many Locations
Multiple Locations, Austria
-
Many Locations
Multiple Locations, Germany
-
Many Locations
Multiple Locations, Greece
-
Many Locations
Multiple Locations, Italy
-
Many Locations
Multiple Locations, Slovenia
-
Many Locations
Multiple Locations, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A Once-a-Week shot could transform hemophilia Care—Even for those with inhibitors
- Can a new clotting factor offer better bleed protection for severe hemophilia?
- Do newer hemophilia drugs protect joints better? study aims to find out
- Newborn screening study aims to catch rare diseases at birth
- Could home blood tests transform hemophilia care? study seeks patient views
- New clotting factor shows promise for hemophilia a bleeds